Cargando…

An isoform of AIF1 involved in breast cancer

BACKGROUND: Inflammation is a major player in breast cancer (BC) progression. Allograft-inflammatory factor-1 (AIF1) is a crucial mediator in the inflammatory response. AIF1 reportedly plays a role in BC, but the mechanism remains to be elucidated. We identified two AIF1 isoforms, AIF1v1 and AIF1v3,...

Descripción completa

Detalles Bibliográficos
Autores principales: Slim, Ferial Amira, Ouellette, Geneviève, Ennour-Idrissi, Kaoutar, Jacob, Simon, Diorio, Caroline, Durocher, Francine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198497/
https://www.ncbi.nlm.nih.gov/pubmed/30386176
http://dx.doi.org/10.1186/s12935-018-0663-3
_version_ 1783364976434479104
author Slim, Ferial Amira
Ouellette, Geneviève
Ennour-Idrissi, Kaoutar
Jacob, Simon
Diorio, Caroline
Durocher, Francine
author_facet Slim, Ferial Amira
Ouellette, Geneviève
Ennour-Idrissi, Kaoutar
Jacob, Simon
Diorio, Caroline
Durocher, Francine
author_sort Slim, Ferial Amira
collection PubMed
description BACKGROUND: Inflammation is a major player in breast cancer (BC) progression. Allograft-inflammatory factor-1 (AIF1) is a crucial mediator in the inflammatory response. AIF1 reportedly plays a role in BC, but the mechanism remains to be elucidated. We identified two AIF1 isoforms, AIF1v1 and AIF1v3, which were differentially expressed between affected and unaffected sisters from families with high risk of BC with no deleterious BRCA1/BRCA2 mutations (BRCAX). We investigated potential functions of AIFv1/v3 in BC of varying severity and breast adipose tissue by evaluating their expression, and association with metabolic and clinical parameters of BC patients. METHODS: AIF1v1/v3 expression was determined in BC tissues and cell lines using quantitative real-time PCR. Potential roles and mechanisms were examined in the microenvironment (fibroblasts, adipose tissue, monocytes and macrophages), inflammatory response (cell reaction in BC subgroups), and metabolism [treatment with docosahexaenoic acid (DHA)]. Association of AIF1 transcript expression with clinical factors was determined by Spearman’s rank correlation. Bioinformatics analyses were performed to characterize transcripts. RESULTS: AIF1v1/v3 were mostly expressed in the less severe BC samples, and their expression appeared to originate from the tumor microenvironment. AIF1 isoforms had different expression rates and sources in breast adipose tissue; lymphocytes mostly expressed AIF1v1 while activated macrophages mainly expressed AIF1v3. Bioinformatics analysis revealed major structural differences suggesting distinct functions in BC progression. Lymphocytes were the most infiltrating cells in breast tumors and their number correlated with AIF1v1 adipose expression. Furthermore, DHA supplementation significantly lowered the expression of AIF1 isoforms in BRCAX cell lines. Finally, the expression of AIF1 isoforms in BC and breast adipose tissue correlated with clinical parameters of BC patients. CONCLUSIONS: Results strongly suggest that AIF1v1 as much as AIF1v3 play a major role in the crosstalk between BC and infiltrating immune cells mediating tumor progression, implying their high potential as target molecules for BC diagnostic, prognostication and treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12935-018-0663-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6198497
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-61984972018-10-31 An isoform of AIF1 involved in breast cancer Slim, Ferial Amira Ouellette, Geneviève Ennour-Idrissi, Kaoutar Jacob, Simon Diorio, Caroline Durocher, Francine Cancer Cell Int Primary Research BACKGROUND: Inflammation is a major player in breast cancer (BC) progression. Allograft-inflammatory factor-1 (AIF1) is a crucial mediator in the inflammatory response. AIF1 reportedly plays a role in BC, but the mechanism remains to be elucidated. We identified two AIF1 isoforms, AIF1v1 and AIF1v3, which were differentially expressed between affected and unaffected sisters from families with high risk of BC with no deleterious BRCA1/BRCA2 mutations (BRCAX). We investigated potential functions of AIFv1/v3 in BC of varying severity and breast adipose tissue by evaluating their expression, and association with metabolic and clinical parameters of BC patients. METHODS: AIF1v1/v3 expression was determined in BC tissues and cell lines using quantitative real-time PCR. Potential roles and mechanisms were examined in the microenvironment (fibroblasts, adipose tissue, monocytes and macrophages), inflammatory response (cell reaction in BC subgroups), and metabolism [treatment with docosahexaenoic acid (DHA)]. Association of AIF1 transcript expression with clinical factors was determined by Spearman’s rank correlation. Bioinformatics analyses were performed to characterize transcripts. RESULTS: AIF1v1/v3 were mostly expressed in the less severe BC samples, and their expression appeared to originate from the tumor microenvironment. AIF1 isoforms had different expression rates and sources in breast adipose tissue; lymphocytes mostly expressed AIF1v1 while activated macrophages mainly expressed AIF1v3. Bioinformatics analysis revealed major structural differences suggesting distinct functions in BC progression. Lymphocytes were the most infiltrating cells in breast tumors and their number correlated with AIF1v1 adipose expression. Furthermore, DHA supplementation significantly lowered the expression of AIF1 isoforms in BRCAX cell lines. Finally, the expression of AIF1 isoforms in BC and breast adipose tissue correlated with clinical parameters of BC patients. CONCLUSIONS: Results strongly suggest that AIF1v1 as much as AIF1v3 play a major role in the crosstalk between BC and infiltrating immune cells mediating tumor progression, implying their high potential as target molecules for BC diagnostic, prognostication and treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12935-018-0663-3) contains supplementary material, which is available to authorized users. BioMed Central 2018-10-22 /pmc/articles/PMC6198497/ /pubmed/30386176 http://dx.doi.org/10.1186/s12935-018-0663-3 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Primary Research
Slim, Ferial Amira
Ouellette, Geneviève
Ennour-Idrissi, Kaoutar
Jacob, Simon
Diorio, Caroline
Durocher, Francine
An isoform of AIF1 involved in breast cancer
title An isoform of AIF1 involved in breast cancer
title_full An isoform of AIF1 involved in breast cancer
title_fullStr An isoform of AIF1 involved in breast cancer
title_full_unstemmed An isoform of AIF1 involved in breast cancer
title_short An isoform of AIF1 involved in breast cancer
title_sort isoform of aif1 involved in breast cancer
topic Primary Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198497/
https://www.ncbi.nlm.nih.gov/pubmed/30386176
http://dx.doi.org/10.1186/s12935-018-0663-3
work_keys_str_mv AT slimferialamira anisoformofaif1involvedinbreastcancer
AT ouellettegenevieve anisoformofaif1involvedinbreastcancer
AT ennouridrissikaoutar anisoformofaif1involvedinbreastcancer
AT jacobsimon anisoformofaif1involvedinbreastcancer
AT dioriocaroline anisoformofaif1involvedinbreastcancer
AT durocherfrancine anisoformofaif1involvedinbreastcancer
AT slimferialamira isoformofaif1involvedinbreastcancer
AT ouellettegenevieve isoformofaif1involvedinbreastcancer
AT ennouridrissikaoutar isoformofaif1involvedinbreastcancer
AT jacobsimon isoformofaif1involvedinbreastcancer
AT dioriocaroline isoformofaif1involvedinbreastcancer
AT durocherfrancine isoformofaif1involvedinbreastcancer